News

An interactive electronic storybook, or e-book, designed to help children with atypical hemolytic uremic syndrome (aHUS) better understand their rare disease, has been launched by Alexion, AstraZeneca Rare Disease, which markets two aHUS therapies. Called “Revealing the Secrets of aHUS,” the fantasy e-book uses imaginative play to…

Timely diagnosis and aggressive treatment were crucial for the recovery of a 26-year-old woman who was diagnosed with atypical hemolytic uremic syndrome (aHUS) after she was induced at 30 weeks of pregnancy, researchers in China report. “Clinical data and treatment experiences related to pregnancy-associated aHUS remain limited. This…

In a “challenging case,” clinicians found a mutation in the membrane cofactor protein gene, or MCP/CD46, in a 23-year-old man with atypical hemolytic uremic syndrome (aHUS). In reporting the case, the researchers stressed the “critical role of genetic testing” in patient evaluations, highlighting the need to be aware of…

COVID-19 triggered atypical hemolytic uremic syndrome (aHUS) in a 13-year-old boy with a genetic predisposition to the syndrome, a recent case study reports. Treatment with plasma exchange therapy, a type of blood-cleansing procedure, was effective, and the boy fully recovered. “This case highlights the potential of COVID-19 to trigger…

A previously healthy 20-year-old woman developed atypical hemolytic uremic syndrome (aHUS) after having surgery to remove her gallbladder shortly after giving birth, according to a recent case study. The woman was treated successfully with Soliris (eculizumab) and with no complications. The case shows “minimally invasive surgeries done within…

Under a new commercialization agreement with Samsung Bioepis, the developer of Epysqli (eculizumab-aagh), Teva Pharmaceuticals will have exclusive marketing rights in the U.S. for the Soliris (eculizumab) biosimilar — an approved treatment for atypical hemolytic uremic syndrome (aHUS). A biosimilar is a biological product that is highly similar to…

The use of a C5 inhibitor — with or without plasma exchange — was found to work better than supportive care to treat kidney problems in women who develop atypical hemolytic uremic syndrome (aHUS) as a complication of bleeding after giving birth, a study found. However, the researchers noted…

Disease manifestations that affect the brain, such as seizures, are relatively common with atypical hemolytic uremic syndrome (aHUS), as are digestive symptoms and heart-related problems, a study finds. The study, “Extrarenal manifestations of atypical hemolytic uremic syndrome: a systematic review and meta-analysis,” was published in Pediatric…

A 38-year-old woman in Portugal developed atypical hemolytic uremic syndrome (aHUS) despite showing no typical markers of the disease after she experienced gastrointestinal inflammation, according to a case report. “This case highlights the diagnostic and management challenges in aHUS when traditional disease markers are absent and emphasizes the importance…

Physicians in India described the case of atypical hemolytic uremic syndrome (aHUS) that manifested as loss of vision in one eye in a 30-year-old man. The patient was successfully managed with plasma therapy, because Soliris (eculizumab) was not available. “This is the first described case to our knowledge…